TickerTalks
Browse all tickers →
TickerTalks›$AARD
AAAARD

Aardvark Therapeutics, Inc. Common Stock

$AARD·$166M·Biotechnology·Healthcare
$6.33-5.1%YTD-49.8%1Y-42.5%
Mentions · last 7 days
2026-07-09: 1 posts2026-07-10: 194 posts2026-07-11: 677 posts2026-07-12: 20 posts2026-07-13: 37 posts2026-07-14: 4 posts2026-07-15: 4 posts937+4%
Price updated 31m ago·X counts updated 23h ago
AAAARD
$AARDAardvark Therapeutics, Inc. Common Stock
$6.33-5.10%937 posts+4%
AI analysisFundamentalsVoices on X
Loading…

AI verdict & sentimentAI analysisGenerated by AI from underlying data

Top X posts

Today's AI verdict on what's driving $AARD, plus how loud the X conversation is and which way it's leaning.

AI analysis

TickerTalks’ read on the fundamentals and what’s driving the move.

Too early to tellWinding up for a moveAI verdict · as of 2026-07-16

Trading in a tight range and building pressure — a move looks likely soon, but the direction isn't clear yet.

Micro-cap biotech at $6.67 with a 22% 52-week range position — the coil is a clinical-milestone bet, not fundamentals.

Aardvark Therapeutics is a clinical-stage biotech company whose 2026 tape has been -50% YTD with no meaningful revenue. The stock is coiled at 22% of the 52-week range with earnings hitting August 12 as the specific data-point event.

  • The core business is pre-revenue: no reported Q1 revenue, negative FCF yield of -37% reflects real capital consumption, and EPS of -$0.99 shows the balance sheet is under specific stress — this is entirely a clinical-milestone bet, not a fundamentals story.
  • The tape signal is technically coiled: position at 22% of 52-week range with a +6.5% day move suggests real positioning ahead of the August 12 print, but no bundle sentiment data means the setup is entirely driven by mechanics and specific data expectations.
  • The typical micro-cap biotech setup applies: at this price level and with these fundamentals, the equity is a specific option-like bet on clinical progress, and continued capital raises or dilution announcements are the specific risk vector — cash runway is the load-bearing question.

The August 12 Q2 earnings are the near-term arbiter — cash-runway commentary (need clear 12+ months at current burn), any specific clinical-milestone data readout, and pipeline-progress commentary extend the coiling setup. Continued negative FCF without a specific clinical catalyst confirms the too-early framing and drops the tape below $5.

What to watch: The August 12 Q2 earnings. Watch cash-runway commentary (need clear 12+ months), specific clinical-milestone data readouts, and pipeline-progress commentary. Continued negative FCF without a specific clinical catalyst confirms too-early framing sub-$5; specific data extends the coil.

On the calendar: 2026-08-12 — Q2 earnings

Read the AI verdict + X sentiment for $AARD

  • One-line verdict on what's driving the move — fundamentals, momentum, both, or an event
  • Next dated catalyst when there is one (earnings, deal closing, activist clock)
  • X crowd read with bullish/bearish call + post volume
Free, forever. No credit card.

What it does

Plain-English summary of the business — what they sell and how they make money.

Clinical-stage biotech developing gut-targeted small molecules for metabolic disorders; lead drug ARD-101 is in Phase III for hyperphagia.

Industry overviewAI analysisGenerated by AI from underlying data

Where Biotechnology sits in its cycle right now — and what that implies for $AARD.

Biotechnology · Healthcare

No material change from last week — ADA conference oral formulation competition is bifurcating biotech multiples between GLP-1 platform holders and precision oncology innovators.

What this means for $AARD

Partial — ARD-101 is currently undergoing a Phase III clinical trial for managing excessive hunger (hyperphagia) associated with Prader-Willi Syndrome; this segment overlaps with the GLP-1 pipeline bifurcation and ADA oral formulation competition but is not the dominant revenue driver.

Top industry ETF

$IBBiShares Biotechnology ETF
+11.9%YTD
+47.2%1Y

Fundamentals & catalyst

Profitability, valuation, and the next earnings event — at a glance, with rule-of-thumb signals.

Key ratios

P/E
-2.4How much investors are paying per dollar of profit the company actually earned in the last 12 months. Lower means the stock looks cheaper relative to earnings.~15–25 is typical for the S&P 500; high-growth names trade 30+; hyper-growth or speculative can be 100+ or negative.
ROIC
-85.6%What percentage return the business earns on every dollar of capital (equity + debt) deployed in operations. The cleanest measure of business quality.Above ~15% is high-quality; consistently above 25% suggests a real moat. Below the company's cost of capital is value-destroying.
Op margin
0.0%Operating profit (after sales, marketing, R&D, and overhead but before interest and taxes) as a percentage of revenue. The clearest view of how well the underlying business is run.Mature business above 20% is healthy; software businesses can run 30%+; commodity / retail businesses operate in single digits.
FCF yield
-37.2%Free cash flow (operating cash flow minus capex) divided by the company's market cap. The cash-on-cash return you'd get owning the whole business at today's price.Above ~5% is attractive; below ~2% means you're paying up for growth. Capital-light businesses (software) run higher than capital-heavy ones (utilities).
P/S
0.0Same idea as P/E but per dollar of revenue. Useful for companies that aren't profitable yet, where P/E is meaningless.Under ~2 is cheap; software / SaaS often runs 8–15; well above 20 implies the market is pricing in very high future growth.
ROE
-61.7%Net income as a percentage of shareholders' equity. Similar to ROIC but counts only the equity side.Above 20% is strong, but can be inflated by leverage — a heavily indebted company can show high ROE with weak underlying ROIC.
Gross margin
0.0%Revenue minus the direct cost of producing what was sold, as a percentage of revenue. The first read on whether the product is structurally profitable.Software / SaaS is typically 70%+; consumer goods 30–50%; commodity / hardware businesses can be under 20%.
D/E
0.0Total debt divided by shareholders' equity. Measures how much the business runs on borrowed money versus owner capital.Under 1 is conservative; 1–2 is typical for mature businesses; over 2 is leveraged and more sensitive to interest rates.

Past earnings

QuarterReportedActualEstimateSurprise
Q1 2026May 7, 2026$-0.99$-0.87-14.0%
Q4 2025Mar 23, 2026$-0.81$-0.83+2.1%
Q3 2025Nov 13, 2025$-0.75$-0.80+6.1%
Q2 2025Aug 13, 2025$-0.66$-0.60-10.0%
Next earningsWed, Aug 12·consensus EPS $-0.86

Quarterly trend

QuarterRevenueYoYGrossOpEPSFCF
Q1 FY26$0———$-0.99$-18.9M
Q4 FY25$0———$-0.81$-14.4M
Q3 FY25$0———$-0.75$-18.5M
Q2 FY25$0———$-0.66$-9.9M

Forward consensus

5-year forecast · up to 10 analysts
FYRevenueRangeEPSRangeAnalysts
FY26$300K$300K – $300K-$3.59-$4.56 – -$2.2810
FY27$1.0M$1.0M – $1.0M-$3.26-$4.27 – -$1.716
FY28$6.6M$6.6M – $6.6M-$2.93-$5.28 – -$1.447
FY29$89.0M$89.0M – $89.0M-$1.64-$1.64 – -$1.643
FY30$277.7M$277.7M – $277.7M$0.62$0.62 – $0.626

Setup & momentum

Volume, range, and moving-average position — the technical setup driving short-term moves.

Right now

Vol vs 30dToday's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.0.5×Today's traded share volume divided by the average over the prior 30 trading days. ≥3× signals unusual interest; below 1× is quiet.
52w rangeWhere the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.23%Where the latest close sits between the 52-week low (0%) and high (100%). Above 80% is extended; below 30% is basing or in a downtrend.
vs 50d MALatest close vs the 50-day simple moving average. Positive = short-term trend is up.+37.6%Latest close vs the 50-day simple moving average. Positive = short-term trend is up.
vs 200d MALatest close vs the 200-day simple moving average. Positive = long-term trend is up.-26.7%Latest close vs the 200-day simple moving average. Positive = long-term trend is up.

Float & profile

FloatLow float · 10.9M shFree-float shares — the slice of issued stock actually available to trade. Lower buckets squeeze harder on a catalyst.Traded today1.7% of floatToday's volume as a percent of the free float. Above 5% on a single day is unusually high turnover for the available share count.β3.935-year weekly beta vs the S&P 500. Above 1.5 means the stock typically moves more than the index; below 0.8 moves less.

Insider activity

Recent open-market buys and sells by officers and directors — flagged when multiple insiders cluster.

Recent transactions

No open-market buys or sells in the last 180 days.

+ 3 other (3 awards) in window

See when $AARD insiders are putting their own money in

  • Real-time open-market buys and sells from Form 4 filings
  • Cluster-buy detection when multiple insiders pile in at once
  • 30 / 60 / 180-day windows so you can spot building conviction
Free, forever. No credit card.

SEC filings

Material 8-K, 13D, S-3, and 424B5 events from the last 180 days — the filings that actually move the price.

Recent material filings

8-KOfficer or director changeJun 128-K — Item 5.02: Officer or director change
AI summary

Aardvark Therapeutics entered into a retention bonus agreement with CFO/COO Nelson Sun on June 10, 2026, committing to pay a total of $346,500: a $198,000 guaranteed annual bonus for 2026 and a $148,500 retention bonus, both payable on January 1, 2027 subject to continued employment. Termination without cause or resignation for good reason before that date triggers a pro-rated payout. Given the FDA clinical hold placed on ARD-101 (see separate filing), the retention package likely reflects the company's effort to stabilize leadership during a critical regulatory challenge.

424B5Prospectus supplement (offering)Apr 3424B5
8-KMaterial agreementMar 248-K — Item 1.01: Material agreement
S-3Shelf registrationMar 23S-3
8-KOfficer or director changeFeb 128-K — Item 5.02: Officer or director change · Item 8.01: Other event
+ 14 other (3 routine 8-Ks · 2 earnings 8-Ks · 1 ARS · 1 proxy) in window

Recent news

Latest headlines from major outlets, sourced and timestamped — context for whatever just moved.

Aardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSprnewswire.com·22d agoAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSgurufocus.com·27d agoAardvark Therapeutics (AARD) Faces Investor Scrutiny Amid 56% Drop On Clinical Pause For Lead Drug Candidate- HBSSprnewswire.com·28d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aardvark Therapeutics, Inc. - AARDprnewswire.com·35d agoINVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aardvark Therapeutics, Inc. - AARDglobenewswire.com·37d ago

In themes

Explore the broader themes this ticker is being talked about under.

GLP-1 & Weight Loss

More in Biotechnology

Peers in the same group — one click to compare setups, fundamentals, and chatter.

$SEER$QTTB$AGEN$REGN$MRNA$AURA$SLS$ALLO
Voices on X · top 3 · last 7 days

TickerTalks is a research tool, not financial advice. We surface social-attention data; we do not make stock recommendations. Past attention is not predictive of future price movements.

PrivacyTermsSupport